Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| NURIX THERAPEUTICS | 27 | 4 | 0,00 % | ||
| INCYTE | 11 | 25 | +0,82 % | ||
| BIONTECH | 10 | 13 | -1,49 % | ||
| TANGO THERAPEUTICS | 8 | 3 | +0,03 % | ||
| GILEAD SCIENCES | 6 | 5 | -0,43 % | ||
| KYMERA THERAPEUTICS | 5 | 6 | +0,05 % | ||
| SAVARA | 4 | - | +4,42 % | ||
| BIOGEN | 3 | 54 | -0,16 % | ||
| CORMEDIX | 3 | 10 | +1,24 % | ||
| LYELL IMMUNOPHARMA | 3 | 8 | 0,00 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05:17 | UK's GSK in Talks to Acquire Cancer Drugmaker Nuvalent in Deal Worth Over USD9B | 4 | AASTOCKS | ||
| 04:54 | IDEAYA Biosciences prices $300 million stock offering | 2 | Investing.com | ||
| 01:18 | Moderna's Lynch syndrome cancer vaccine trial gets UK approval | 2 | Investing.com | ||
| 01:02 | Moderna, Inc.: Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome | 510 | ACCESS Newswire | Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%[1]The INTERCEPT-Lynch trial is part of a scientific collaboration between the University... ► Artikel lesen | |
| 00:46 | Incyte's $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug | 2 | MedCity News | ||
| Mo | Merck, Gilead share positive phase 3 results from combination HIV pill | 2 | Seeking Alpha | ||
| Mo | 10x Genomics: Aktionäre bestätigen Direktoren und genehmigen Anträge auf Hauptversammlung | 1 | Investing.com Deutsch | ||
| Mo | Gilead and Merck's once-weekly HIV pill meets trial goals | 2 | Investing.com | ||
| Mo | Stifel initiates Enliven Therapeutics stock with buy rating | 1 | Investing.com | ||
| Mo | Stifel startet Coverage für Enliven Therapeutics mit 'Buy'-Rating | 2 | Investing.com Deutsch | ||
| Mo | Ascendis Pharma: Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 | 1 | GlobeNewswire (USA) | ||
| Mo | 10x Genomics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| Mo | Merck and Gilead discontinue lung cancer drug trial | 3 | Investing.com | ||
| Mo | Savara CFO to step down | 1 | Seeking Alpha | ||
| Mo | Savara CFO Dave Lowrance to step down, Robert Lutz to expand role | 1 | Investing.com | ||
| Mo | Tango Therapeutics stock soars on promising pancreatic cancer data | 4 | iNVEZZ.com | ||
| Mo | Savara: CFO Dave Lowrance tritt zurück, COO Robert Lutz erweitert Aufgabenbereich | 2 | Investing.com Deutsch | ||
| Mo | Ideaya Biosciences: Aktie fällt nach Ankündigung einer Kapitalerhöhung über 300 Mio. US-Dollar | 4 | Investing.com Deutsch | ||
| Mo | Tango Therapeutics files for $500 million common stock offering | 3 | Seeking Alpha | ||
| Mo | Savara Inc - 8-K, Current Report | 1 | SEC Filings |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.